ArticleJournal of medicinal chemistry2023

HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies.

A Elisa Pasqua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.